Back

Antiplatelet therapy and outcome in patients with COVID-19. Results from a multi-center international prospective registry (HOPE-COVID19).

29 August 2021 (20:24 - 20:33)
Organised by:
Congress Presentation Part of: COVID-19 and cardiovascular pharmacotherapy Antiplatelet Drugs ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Doctor Francesco Santoro

University of Foggia - Faculty of Medecine, Foggia (Italy)

4 More presentations in this session

Presentation thumbnail
Effect of prophylactic and therapeutic low molecular weight heparins on mortality in 15,704 COVID-19 patients. A systematic review and a meta-analysis.
Doctor A. Pani (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Early experience utilizing bivalirudin as anticoagulation in extracorporeal membrane oxygen in coronavirus disease 2019
Doctor C. Jones (West Palm Beach, US)
Abstract Slides Video
Presentation thumbnail
Effect of statins on mortality in patients with COVID-19: an updated meta-analysis of 147824 patients
Doctor C. Diaz-Arocutipa (Lima, PE)
Abstract Slides Video
Presentation thumbnail
Management and impact of atrial fibrillation in the COVID 19 era; concomitancy of two procoagulant phenomena
Doctor A. Arteagoitia Bolumburu (Mainz, DE)
Abstract Slides Video

Access the full session

Session thumbnail
COVID-19 and cardiovascular pharmacotherapy

The Event

Event poster

ESC Congress 2021 - The Digital Experience

29 August 2021 20:24 CET
You may be interested in
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
thumbnail
Congress Session
State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources